Act Fast: Ensuring Rapid Anaphylaxis Treatment with Intranasal Epinephrine

A panelist discusses how anaphylaxis affects approximately 40 million people in the United States with severe systemic reactions involving multiple organ systems, leading to over 500,000 emergency room visits annually.

A panelist discusses how epinephrine is the first and only evidence-based first-line treatment for anaphylaxis, working through alpha and beta adrenergic receptors to rapidly reverse life-threatening symptoms unlike slower-acting antihistamines.

A panelist discusses how early epinephrine administration significantly reduces severe complications, prevents progression to life-threatening stages, and decreases the need for additional medical interventions like hospitalization or multiple doses.

A panelist discusses how multiple barriers prevent timely epinephrine use, including patient reluctance to use auto-injectors, lack of device availability, uncertainty about administration timing, and cost concerns, leading to widespread underuse.

A panelist discusses how Neffy represents a novel intranasal epinephrine delivery system using three FDA-approved components: epinephrine, Intravail absorption enhancer, and a proven nasal spray device already used in other medications.

A panelist discusses how FDA bracketing studies demonstrated that Neffy's pharmacokinetics and pharmacodynamics fall within the established safety and efficacy range of existing epinephrine auto-injectors, with rapid onset within one minute.

A panelist discusses how real-world studies in Japan showed Neffy successfully treated grade 2 anaphylaxis symptoms in pediatric patients with a median resolution time of 16 minutes and minimal adverse effects.

A panelist discusses how Neffy addresses unmet needs through superior temperature stability (tolerating up to 122°F for 3-4 days), extended shelf life (24-30 months), and needle-free administration that eliminates injection-related complications.

A panelist discusses how shared decision-making between healthcare providers and patients should guide epinephrine device selection, with two real-world case studies demonstrating successful Neffy use in treating anaphylaxis with rapid symptom resolution.